Cargando…

Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma

The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres (ALT). The common defining feature of all three subgroups is altered telomere maintenanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, S. L., Parmar, V., Lorenzi, F., Marshall, L. V., Jamin, Y., Poon, E., Angelini, P., Chesler, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201617/ https://www.ncbi.nlm.nih.gov/pubmed/32375866 http://dx.doi.org/10.1186/s13046-020-01582-2

Ejemplares similares

Reliable assessment of telomere maintenance mechanisms in neuroblastoma
por: Meeser, Alina, et al.
Publicado: (2022)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
por: Nijhuis, Anke, et al.
Publicado: (2022)

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
por: Yu, Eun Young, et al.
Publicado: (2022)

Telomere Maintenance Mechanisms in Cancer
por: Bordeira Gaspar, Tiago, et al.
Publicado: (2018)

The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2021)

Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma
por: Yu, Eun Young, et al.
Publicado: (2019)

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018)

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
por: George, Sally L, et al.
Publicado: (2020)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas
por: Naderlinger, Elisabeth, et al.
Publicado: (2017)

Telomere Maintenance Mechanisms in Cancer: Clinical Implications
por: Reddel, Roger R
Publicado: (2014)

New insight into telomere maintenance
por: Wu, Ryan T.Y., et al.
Publicado: (2010)

Ubiquitination and SUMOylation in Telomere Maintenance and Dysfunction
por: Yalçin, Zeliha, et al.
Publicado: (2017)

Physical Activity and Nutrition: Two Promising Strategies for Telomere Maintenance?
por: Balan, Estelle, et al.
Publicado: (2018)

Genomic footprints of activated telomere maintenance mechanisms in cancer
por: Sieverling, Lina, et al.
Publicado: (2020)

The telomere maintenance mechanism spectrum and its dynamics in gliomas
por: Kim, Sojin, et al.
Publicado: (2022)

Telomere Maintenance-Associated PML Is a Potential Specific Therapeutic Target of Human Colorectal Cancer
por: Gong, Peng, et al.
Publicado: (2019)

Telomere Targeting Approaches in Cancer: Beyond Length Maintenance
por: Vertecchi, Eleonora, et al.
Publicado: (2022)

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
por: King, David, et al.
Publicado: (2020)

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
por: Wong, Matthew, et al.
Publicado: (2019)

Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
por: King, David, et al.
Publicado: (2023)

The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets
por: Huang, Shaohui, et al.
Publicado: (2022)

Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance
por: Fransson, Susanne, et al.
Publicado: (2020)

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation
por: Ferreira, Monica Sofia Ventura, et al.
Publicado: (2020)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

Non-invasive assessment of telomere maintenance mechanisms in brain tumors
por: Viswanath, Pavithra, et al.
Publicado: (2021)

Telomere Maintenance in Pediatric Cancer
por: Ackermann, Sandra, et al.
Publicado: (2019)

Human RECQL1 participates in telomere maintenance
por: Popuri, Venkateswarlu, et al.
Publicado: (2014)

Human RECQL1 participates in telomere maintenance
por: Popuri, Venkateswarlu, et al.
Publicado: (2017)

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
por: Van Goethem, Alan, et al.
Publicado: (2017)

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma
por: Yan, Hui, et al.
Publicado: (2022)

Long telomeres bypass the requirement for telomere maintenance in human tumorigenesis
por: Taboski, Michael A. S., et al.
Publicado: (2012)

Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma
por: Ram Kumar, Ram Mohan, et al.
Publicado: (2018)

Intratumoral diversity of telomere length in individual neuroblastoma tumors
por: Pezzolo, Annalisa, et al.
Publicado: (2014)

How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
por: Akter, Jesmin, et al.
Publicado: (2021)

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
por: Poon, Evon, et al.
Publicado: (2020)

Arabidopsis AN3 and OLIGOCELLULA genes link telomere maintenance mechanisms with cell division and expansion control
por: Agabekian, Inna A., et al.
Publicado: (2023)

Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential
por: Fernandes, Stina George, et al.
Publicado: (2020)

Telomeres as Therapeutic Targets in Heart Disease
por: Yeh, Jih-Kai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lqm7b8jll2smjiv3fj3k7l8pui